Our Technology

Our technology is based on biocompatible dendritic core multi-shell nanocarriers. This technology was developed between 2002 and 2012 in the group of Prof. Dr. Rainer Haag at TU Dortmund and Freie Universität Berlin. The safety and efficiency of our technology have already been tested in vitro and in vivo.

As a platform technology, our carriers can be tailored to the needs of our customers and research partners. By adjusting the polar and nonpolar domains of our carriers, we can, for example, improve loading with a specific active ingredient and thereby increase its solubility and bioavailability.

DendroSol

DendroSol® is a highly amphiphilic carrier that significantly improves the skin penetration of both lipophilic and hydrophilic drugs, particularly poorly soluble or highly lipophilic ones. It facilitates transport through the stratum corneum and delivers 2- to 14-fold higher drug concentrations in deeper skin layers compared with conventional formulations. DendroSol® is non-toxic and non-irritating and has proven effective with substances such as doxorubicin, dexamethasone, sagopilone, nimodipine, Nile red and rhodamine B (literature).

Functionalized DendroSol® and gels based on our dendritic polyglycerols deliver active ingredients specifically into hair follicles, which also makes them of interest for cosmetic applications. Active ingredient savings by a factor of 3–5 have been documented in the literature (1, 2).

DendroCarrier

DendroCarrier™ carriers accumulate selectively in tumor tissue and enable controlled, pH-dependent drug release within the tumor microenvironment. This pH-sensitive technology, developed together with Freie Universität Berlin, has already been used successfully to encapsulate drugs such as nimodipine and doxorubicin. Initial animal studies show excellent biocompatibility.

DendroCore

DendroCore™ is a highly sulfated, multivalent compound that acts as an effective heparin analog with strong anti-inflammatory and antithrombotic properties. Its efficacy is based on strong binding to P- and L-selectins, which blocks leukocyte adhesion to inflamed tissue and thus interrupts a key step in the inflammatory cascade.

Contact us for more information about our technology.

DendroPharm is interested in collaborations with companies or academic research groups to develop new drugs and novel drug delivery systems.